Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2022—Thermo Fisher Scientific announced an agreement with Inpeco S.A. to develop connectivity between the Thermo Scientific Cascadion SM automated liquid chromatography mass spectrometer and the Inpeco S.A. FlexLab total laboratory automation system.
August 2022—Thermo Fisher Scientific has launched its Applied Biosystems TaqPath Respiratory Viral Select panel. The CE-IVD-marked molecular assay panel provides results in approximately three hours and tests for adenovirus, human metapneumovirus, rhinovirus/enterovirus, and parainfluenza virus using PCR technology. RNase P and positive controls are included to offer sample-to-result reliability. The solution is scalable, allowing laboratories to run from one to 94 samples simultaneously.
Aug. 16, 2022—The FDA granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target test as a companion diagnostic to identify patients whose tumors have HER2 (ERBB2)-activating mutations (single nucleotide variants and exon 20 insertion) in non-small cell lung cancer who may be candidates for Enhertu (fam-trastuzumab deruxtecan-nxki).
July 13, 2022—Thermo Fisher Scientific announced an agreement with Inpeco S.A. to develop connectivity between the Thermo Scientific Cascadion SM automated liquid chromatography mass spectrometer and the Inpeco FlexLab total laboratory automation system.
April 2022—Thermo Fisher Scientific has launched two reverse transcription loop-mediated isothermal amplification (RT-LAMP)–based solutions for research use only. The Invitrogen Colorimetric ReadiLAMP Kit, SARS-CoV-2, is an off-the-shelf assay designed to provide accurate, robust detection of SARS-CoV-2 from saliva, nasal, or nasopharyngeal swab samples. The kit includes two protocols, one for crude sample types with a 30-minute turnaround time and one for increased sensitivity with purified RNA sample types that has a one-hour turnaround time.
November 2021—Thermo Fisher Scientific has updated its research use only Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to include the mu strain. Laboratories can build their own panel from a menu of more than 50 verified real-time PCR assays that allows the user to identify relevant SARS-CoV-2 mutations and adapt as additional mutations and variants emerge.
July 2021—Thermo Fisher Scientific launched its CE-IVD-marked TaqPath COVID-19 Fast PCR Combo Kit 2.0. The kit uses an advanced assay design that compensates for current and emerging variants, the company says, by using eight targets across three genomic regions of the virus to help ensure the test provides accurate results even as the virus mutates.
June 24, 2021—Thermo Fisher Scientific launched its CE-IVD-marked TaqPath COVID-19 Fast PCR Combo Kit 2.0.
June 2021—Thermo Fisher Scientific announced the FDA has expanded emergency use authorization for the Applied Biosystems TaqPath COVID-19 Combo Kit to include the high-throughput Thermo Fisher Scientific Amplitude solution.
April 14, 2021–Thermo Fisher Scientific announced the FDA has expanded emergency use authorization for the Applied Biosystems TaqPath COVID-19 Combo Kit to include the high-throughput Thermo Fisher Scientific Amplitude solution.
